Premium
Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide.
Author(s) -
Jordo L,
Johnsson G,
Lundborg P,
Persson BA,
Regardh CG,
Ronn O
Publication year - 1979
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1979.tb04643.x
Subject(s) - hydrochlorothiazide , metoprolol , bioavailability , pharmacology , pharmacokinetics , chemistry , drug , medicine , blood pressure
1. The plasma levels and the urinary excretion of hydrochlorothiazide (HCT) have been studied after administration of single doses of 12.5 and 25 mg of the drug in solution and in combination with 100 mg of the selective beta 1‐adrenoreceptor antagonist metoprolol in a rapidly dissolving tablet. 2. Metoprolol did not significantly influence the bioavailability or the time‐course of HCT. 3. HCT had no significant effect on the time‐course or the plasma levels of metoprolol. The average half‐life, 4.4 +/‐ 0.9 h, is about the same as previously observed for separate doses of this drug. 4. It seems unlikely that repeated doses of the combination product studied will lead to biopharmaceutic or pharmacokinetic interactions of clinical importance.